title: Executive Functioning Outcomes Over 6 Months of Atomoxetine for Adults With ADHD: Relationship to Maintenance of Response and Relapse Over the Subsequent 6 Months After Treatment.
abstract: Objective:This study examines the relationship between maintenance of improved executive functioning (EF) in adults with ADHD with long-term symptom improvement with atomoxetine.Method:Data were collected from a yearlong, double-blind, placebo-controlled clinical study on adult patients with ADHD receiving atomoxetine (80-100 mg/day) for 24 weeks. Patients were then randomized to continue atomoxetine or placebo for 6 months. Executive functioning was rated with Behavior Rating Inventory of Executive Function-Adult Version: Self-Report™ (BRIEF-A: Self-Report™), and theT-scores were determined.Results:PostrandomizationT-scores for atomoxetine patients were significantly better than those of placebo patients (3 and 6 months postrandomization). Patients with greater improvements in EF were more likely to show worsening of EF and to relapse after atomoxetine discontinuation. The maintenance of improved EF was significantly associated with improved ADHD symptoms (Conners' Adult ADHD Rating Scale-Investigator Rated: Screening Version [CAARS-Inv:SV] with adult prompts).Conclusion:Treatment with atomoxetine improved EF during the treatment phases. Improved EF was maintained up to 6 months after discontinuation of atomoxetine.
authors: New York University Langone Medical Center, New York City, NY, USA.
authors: Lenard A
authors: LA
authors: Adler
authors: New York University Langone Medical Center, New York City, NY, USA.
authors: Mary
authors: M
authors: Solanto
authors: Eli Lilly and Company, Indianapolis, IN, USA.
authors: Rodrigo
authors: R
authors: Escobar
authors: inVentiv Health Clinical, LLC, Ann Arbor, MI, USA.
authors: Sarah
authors: S
authors: Lipsius
authors: Eli Lilly and Company, Indianapolis, IN, USA.
authors: Himanshu
authors: H
authors: Upadhyaya
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D000328:Adult; D000069445:Atomoxetine Hydrochloride / Q000627:therapeutic use; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D004311:Double-Blind Method; D056344:Executive Function; D006801:Humans; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000069445:Atomoxetine Hydrochloride
keywords: ADHD; adults; atomoxetine; executive functioning; maintenance of response